New Treatments for Hepatitis B in 2026
While nucleos(t)ide analogs (NAs) remain the cornerstone of chronic hepatitis B treatment, several investigational therapies are advancing toward functional cure, including antisense oligonucleotides (bepirovirsen), capsid assembly modulators, and immunomodulatory agents, though none are yet FDA-approved for hepatitis B as of 2026.
Current Treatment Landscape
The 2025 EASL guidelines continue to recommend NAs (tenofovir, entecavir) as first-line therapy for chronic hepatitis B 1. Treatment indications have expanded significantly, with recent guidelines from WHO and China broadening access beyond traditional criteria of high HBV DNA (>2,000 IU/ml) and elevated ALT 2.
Key treatment criteria per EASL 2025:
- Mandatory treatment: HBV DNA >2,000 IU/ml with elevated ALT (>ULN) and/or significant fibrosis 1
- Cirrhotic patients: Any detectable HBV DNA regardless of level or ALT 1
- Advanced fibrosis (>F3 or LSM >8 kPa): Any detectable HBV DNA 1
The critical limitation: NAs achieve HBsAg seroclearance (functional cure) in only 3-5% of patients after 10 years of therapy 3.
Investigational Therapies in Development
Antisense Oligonucleotides: Bepirovirsen
Bepirovirsen is the most clinically advanced novel agent, showing promising results in phase II trials 4. This modified antisense oligonucleotide directly targets HBV RNA to reduce viral antigen production. While it demonstrates a good safety profile and potential for HBsAg reduction, it requires further investigation in larger patient populations to confirm functional cure rates 4.
Important caveat: The FDA drug label evidence provided 5 actually describes BESREMi (ropeginterferon alfa-2b) for polycythemia vera, NOT bepirovirsen for hepatitis B. This appears to be a data error and should not influence hepatitis B treatment decisions.
Capsid Assembly Modulators (CAMs)
CAMs represent a novel mechanism targeting HBV capsid formation. First-generation agents like vebicorvir have completed phase I trials, demonstrating biphasic declines in HBV DNA and RNA 6. These agents show mechanistic differences in effectiveness between HBeAg-positive and HBeAg-negative patients 6. CAMs are being investigated as part of combination strategies to enhance functional cure rates 7, 8.
Immunomodulatory Approaches
Multiple immune-based strategies are under investigation 7, 8, 3:
- TLR-7/8 agonists: Enhance innate immune responses
- Immune checkpoint inhibitors: Restore HBV-specific T-cell function
- Therapeutic vaccines: Multiple platforms including protein-based, DNA-based, peptide-based, and live vector-based vaccines are in various stages of development 7, 9
Critical limitation: Therapeutic vaccines have shown "promising efficacies" in preclinical and clinical trials but none have achieved regulatory approval for routine use 9.
Other Direct-Acting Antivirals
Additional investigational agents target different stages of the HBV life cycle 7, 3:
- HBV entry inhibitors: Block viral cell entry
- Monoclonal antibodies: Neutralize circulating virus
- RNA interference (RNAi): Small interfering RNAs to suppress viral gene expression
The Path Forward: Combination Strategies
The consensus among experts is that combination therapy will likely be necessary to achieve meaningful functional cure rates 7, 3. Rational combination designs pairing direct-acting antivirals with immunomodulators show the most promise for overcoming the barriers of cccDNA persistence and HBV DNA integration 3.
Clinical Implications for 2026
For current practice:
- Continue NAs as standard of care for eligible patients per EASL 2025 guidelines 1
- Consider expanded treatment criteria, particularly for patients >30 years, those with family history of HCC/cirrhosis, or any detectable HBV DNA with evidence of liver inflammation 2
- Monitor clinical trial results for emerging therapies, particularly bepirovirsen and CAM-based combinations
- Recognize that achieving functional cure (HBsAg loss) remains the ultimate goal but is not yet reliably achievable with current or immediately available therapies
Common pitfall: Do not confuse viral suppression (achievable with NAs) with functional cure (HBsAg loss). While NAs effectively prevent disease progression, cirrhosis, and HCC, they rarely eliminate the virus 2, 3.
The landscape is evolving rapidly, with the goal of HBV elimination by 2030 driving intensive research 4, but as of 2026, no new agents have achieved regulatory approval beyond traditional NAs and pegylated interferon.